Barbara Klencke - 13 Jun 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Director
Signature
/s/ Barbara Klencke
Issuer symbol
TCRX
Transactions as of
13 Jun 2023
Net transactions value
$0
Form type
4
Filing time
15 Jun 2023, 18:13:36 UTC
Previous filing
10 Apr 2023
Next filing
22 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +36,524 $0.000000 36,524 13 Jun 2023 Voting Common Stock 36,524 $2.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 35,000 shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, with 1,524 shares subject to this option vesting and becoming exercisable in full on June 13, 2023, in each case subject to the Reporting Person's continued service at such time.